Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.61 |
| ▸ | CCND1 | P24385 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30057745 | 1.00 | CDK4 (0.61) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL30630289 | 0.81 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL2080600 | 0.81 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL20417796 | 0.81 | CDK4 (0.57) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL31083788 | 0.78 | CDK4 (0.70) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL3995842 | 0.78 | CDK4 (0.70) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL1629560 | 0.77 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL29433250 | 0.77 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL3434514 | 0.77 | HTT (0.55) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL27467119 | 0.77 | KMT2A (0.56) | CDK4CCND1HTR2AHTR2CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753421-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753421-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753421-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-09-12 | — | — | US | disclosed |
| CN-111253424-B | Silylation of aromatic heterocycles over earth-rich transition metal-free catalysts | 加州理工学院 | 2023-06-20 | — | — | CN | disclosed |
| EP-3705482-B1 | SILYLATION OF AROMATIC HETEROCYCLES BY EARTH ABUNDANT TRANSITION-METAL-FREE CATALYSTS | CALIFORNIA INST OF TECHN (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-113527022-B | Asymmetric polysulfide compound and its synthesis method and use | 华东师范大学 | 2022-12-06 | — | — | CN | disclosed |
| US-20220185828-A1 | Silylated Derivatives Of Aromatic Heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-06-16 | — | — | US | disclosed |
| US-20220185828-A1 | Silylated Derivatives Of Aromatic Heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-06-16 | — | — | US | disclosed |
| US-11312733-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312733-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-04-26 | — | — | US | disclosed |
| US-5736544-A | ADMINISTERING TO TREAT MIGRAINE HEADACHES IN MAMMALS | ELI LILLY AND COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| US-5705519-A | ADMINISTERING A SUBSTITUTED INDOLE TO A MAMMAL | ELI LILLY AND COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5688807-A | ANTIDEPRESSANTS, ANXIETY, UROGENITAL DISORDERS, HYPOTENSIVES, CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY (US) | 1997-11-18 | — | — | US | disclosed |
| US-5635528-A | RECEPTOR BINDING MODULATORS, FOR CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0749313-A1 | METHOD FOR TREATING 5HT 2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5508284-A | TREATING 5-HYDROXYTRYPTAMINE MODULATION | ELI LILLY AND COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5500431-A | ANTISEROTONINE AGENTS; SEXUAL AND EATING DISORDERS | ELI LILLY AND COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| WO-1995024200-A1 | METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1994023720-A1 | TETRAHYDRO-BETA-CARBOLINES | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0620222-A2 | Tetrahydro-beta-carbolines | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312733-B2 | Silylated derivatives of aromatic heterocycles | KCNH1, KCNH3, HNRNPH3 | CDK4 1950/4885CCND1 1890/4885HTR2A 1777/4885 |
| US-11753421-B2 | Silylated derivatives of aromatic heterocycles | KCNH1, KCNH3, HNRNPH3 | CDK4 1950/4885CCND1 1890/4885HTR2A 1777/4885 |
| US-20220185828-A1 | Silylated Derivatives Of Aromatic Heterocycles | KCNH1, KCNH3, HNRNPH3 | CDK4 1950/4885CCND1 1890/4885HTR2A 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.